期刊文献+

高效液相色谱法测定雷西纳德原料药的含量

Determination of Content in Lesinurad by HPLC
下载PDF
导出
摘要 建立了高效液相色谱法测定雷西纳德原料药的含量。色谱柱为Luna C18(2)100A(150×4.6 mm,5μm);以甲醇-2%冰醋酸溶液(60:40)为流动相;流速1.0 ml•min^(-1),检测波长为290 nm。雷西纳德在浓度为10.19~50.94μg•ml^(-1)范围内与峰面积的线性关系良好(r=0.9998,n=5),平均回收率为99.68%(RSD为0.62%,n=9),8h溶液稳定性试验的RSD为0.46%,重复性试验的RSD为0.51%(n=6),雷西纳德和相邻峰之间的分离度良好。经方法学验证,该法适用于雷西纳德原料药的含量测定。 To establish an HPLC method to determine the content of Lesinurad.The analysis was achieved on a Luna C18(2)100A column(150×4.6mm,5μm),and used a mobile phase of methanol and 2%glacial acetic acid solution(60:40).The flow rate was 1.0 ml·min^(-1,)and the detection wavelength was 290nm.There was a good linear relationship between the peak area and the concentration in the range of 10.19~50.94μg•ml^(-1)(r=0.9998,n=5),the mean recovery was 99.68%(RSD=0.62%,n=9),the RSD of the 8h stability test was 0.46%,the RSD of the repeatability test was 0.51%,the resolution between Lesinurad and its adjacent peaks was achieved.The method of validation showed that it can be used for the determination of content of Lesinurad.
作者 苏有为 王新妍 晏斐 朱海 黄艳 SU You-wei;WANG Xin-yan;YAN Fei;ZHU Hai;HUANG Yan(School of Pharmacy,Hainan Medical University,Haikou 571199,China)
出处 《化工管理》 2021年第30期145-146,共2页 Chemical Engineering Management
基金 海南医学院大学生创新创业训练计划项目(S202011810026)资助课题。
关键词 高效液相色谱法 雷西纳德 含量 HPLC Lesinurad content
  • 相关文献

参考文献2

二级参考文献18

  • 1Michael D, Jansen T L, George N, et al. Gout: why is this curable disease so seldom cured [J]. Ann Rheum Dis, 2012, 71(11): 1765-1770.
  • 2Pema K M. lesinuard sodium [J]. Drugs Fut, 2011, 36(12): 875.
  • 3Yeh L, Hingorani V, Manhard K, et al. Safety and uric acid lowering effect in humans following multiple doses of RDEA806, a novel prodrug for the potential treatment of hyperuricemia [J]. Ann Rheum Dis, 2008, 67: 248.
  • 4Yeh L, Tamai I, Hamatake R, et al. Mode of action of RDEA594 as a uric acid lowering agent in humans following multiple doses of its prodrug RDEA806 [J]. Ann Rheum Dis, 2008, 67(Suppl Ⅱ): 249.
  • 5Enomoto A, Kimura H, Chairoungdu A, et al. Molecular identification of a renal urate anion exchanger thatregulates blood urate levels [J]. Nature, 2002, 17: 447-452.
  • 6Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules [J]. Nucleosides Nucleotides Nucleic Acids, 2008, 27(6): 578-584.
  • 7Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter [J]. JAm Soc Nephrol, 2007, 18(2): 430-439.
  • 8Yeh L T, Shen Z, Kerr B, et al. RDEA594, a potent URAT1 inhibitor without affecting other important renal transporters OAT1 and OAT3 [J]. Ann Rheum Dis, 2009, 68(Supp13): 320.
  • 9Yang X Q, Dick R, Borges V, et al. Evaluation of drug-drug interaction potential between RDEA594, allopurinol and febuxostat in preclinicalspecies [J]. Arthritis Rheum, 2009, 60: 412-413.
  • 10Yeh L, Yang J, Theiss J, et al. RDEA594, a potential uric acid lowering agent through inhibition of uric acid reuptake, shows better pharmacokinetics than its prodrug RDEA806 [C]. San Francisco: 2008 Annual Scientific Meeting, 2008.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部